Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transarterial Chemoembolization Combined With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase II, Single-Arm Clinical Trial

NCT07281664 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT07281664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07281664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transarterial Chemoembolization Combined With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase II, Single-Arm Clinical Trial
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
December 31, 2029
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, transarterial chemoembolization